Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 47 Pages
|Tysabri(克隆氏症)- 預測與市場分析 Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年01月31日||內容資訊: 英文 47 Pages||
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Tysabri (natalizumab), which was discovered by Elan, is a recombinant humanized immunoglobulin G4 (IgG4) mAb that acts as a selective α-4 integrin inhibitor. It binds to the α4-subunit of α4ß1 and α4ß7 integrins expressed on the surface of leukocytes and inhibits their α4-mediated adhesion to mucosal VCAM-1 and MadCAM-1 receptors, respectively. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into inflamed tissue. Tysabri was initially approved for the treatment of MS, and gained approval in the US in 2008 for use in CD as a second-line therapy.